GEN vs. CDAY, CCCS, ZI, SVFCX, SEMR, MIXT, XPER, IDN, MAQC, and MTBLY
Should you be buying Genesis Healthcare stock or one of its competitors? The main competitors of Genesis Healthcare include Ceridian HCM (CDAY), CCC Intelligent Solutions (CCCS), ZoomInfo Technologies (ZI), Smead Value C (SVFCX), Semrush (SEMR), MiX Telematics (MIXT), Xperi (XPER), Intellicheck (IDN), Maquia Capital Acquisition (MAQC), and Moatable (MTBLY).
Genesis Healthcare vs. Its Competitors
Genesis Healthcare (NYSE:GEN) and Ceridian HCM (NYSE:CDAY) are both large-cap prepackaged software industry companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.
Genesis Healthcare has a net margin of 17.83% compared to Ceridian HCM's net margin of 0.28%. Genesis Healthcare's return on equity of 155.48% beat Ceridian HCM's return on equity.
Genesis Healthcare has higher revenue and earnings than Ceridian HCM. Genesis Healthcare is trading at a lower price-to-earnings ratio than Ceridian HCM, indicating that it is currently the more affordable of the two stocks.
Genesis Healthcare has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Ceridian HCM has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.
In the previous week, Ceridian HCM had 3 more articles in the media than Genesis Healthcare. MarketBeat recorded 4 mentions for Ceridian HCM and 1 mentions for Genesis Healthcare. Ceridian HCM's average media sentiment score of 0.32 beat Genesis Healthcare's score of 0.00 indicating that Ceridian HCM is being referred to more favorably in the news media.
Genesis Healthcare currently has a consensus target price of $33.25, suggesting a potential upside of 6.60%. Given Genesis Healthcare's stronger consensus rating and higher possible upside, equities analysts plainly believe Genesis Healthcare is more favorable than Ceridian HCM.
82.1% of Genesis Healthcare shares are held by institutional investors. 3.3% of Genesis Healthcare shares are held by company insiders. Comparatively, 4.5% of Ceridian HCM shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Genesis Healthcare beats Ceridian HCM on 10 of the 16 factors compared between the two stocks.
Get Genesis Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for GEN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genesis Healthcare Competitors List
Related Companies and Tools
This page (NYSE:GEN) was last updated on 8/22/2025 by MarketBeat.com Staff
MarketBeat All Access